Sepsis is a disease with high mortality. [@JR02477-1] [@JR02477-2] [@JR02477-3] [@JR02477-4] [@JR02477-5] [@JR02477-6] [@JR02477-7] However, the original notion of sepsis as the invasion of blood and tissues by pathogenic microorganisms has long come to be replaced, in the antibiotic era, by the recognition that in many cases, the main causes of death arise not so much from the replication of the pathogen per se but from the host\'s "innate immune" *response* to the pathogen. [@JR02477-8] [@JR02477-9] [@JR02477-10] [@JR02477-11] In particular, microbial replication is not even necessary (and most bacteria in nature are dormant [@JR02477-12] [@JR02477-13] [@JR02477-14] [@JR02477-15] [@JR02477-16] ), as this response is driven by very potent [@JR02477-17] inflammation-inducing agents such as the lipopolysaccharides (LPSs) of gram-negative bacteria [@JR02477-18] and equivalent cell wall materials such as lipoteichoic acids from gram-positive bacteria. [@JR02477-19] [@JR02477-20] [@JR02477-21] [@JR02477-22] To this end, such release may even be worsened (i.e., the Jarisch--Herxheimer reaction [@JR02477-23] [@JR02477-24] [@JR02477-25] [@JR02477-26] ) by antibiotic therapy. [@JR02477-27] [@JR02477-28] [@JR02477-29] [@JR02477-30] In unfavorable cases, this leads to an established cascade ( [Fig. 1](#FI02477-1){ref-type="fig"} ) [@JR02477-31] in which the innate immune response, involving proinflammatory cytokines such as interleukins 6, 8, and 1β, monocyte chemoattractant protein-1, and tissue necrosis factor α, [@JR02477-32] becomes a "cytokine storm" [@JR02477-33] [@JR02477-34] [@JR02477-35] [@JR02477-36] [@JR02477-37] leading to a "systemic inflammatory response syndrome" (SIRS), [@JR02477-38] [@JR02477-39] [@JR02477-40] [@JR02477-41] [@JR02477-42] [@JR02477-43] septic shock, [@JR02477-4] multiple organ failure [@JR02477-44] (MOF, also known as multiple organ dysfunction syndrome, MODS [@JR02477-45] [@JR02477-46] ), and finally organismal death. All of the above is well known and may be taken as a noncontroversial background. Nevertheless, it is still unclear whether apoptotic [@JR02477-47] and necrotic [@JR02477-48] cell death is minimal [@JR02477-49] or significant. Despite this knowledge, "the recent inability of activated protein C to show an outcome benefit in a randomized controlled multicenter trial [@JR02477-2] and the subsequent withdrawal of the product from commercial use add to the growing stockpile of failed therapeutics for sepsis." [@JR02477-50] (This last failure was probably due to an excessively anticoagulant activity.)

![A standard cascade illustrating the progression of infection through sepsis, systemic inflammatory response syndrome, and death.](10-1055-s-0037-1604108-i02477-1){#FI02477-1}

Most recently [@JR02477-51] (but see also Churpek et al [@JR02477-52] ), definitions of sepsis have come to be based on organ function and the Sequential (Sepsis-Related) Organ Failure Assessment (SOFA) Scores. [@JR02477-53] These latter take into account the multisystem nature of sepsis and include respiratory, hemostatic (but only based on platelet counts), hepatic, cardiovascular, renal, and central nervous system measurements. A SOFA score of 2 or greater typically means at least a 10% mortality rate. Specifically, sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. Septic shock is defined as a subset of sepsis in which underlying circulatory and cellular metabolism abnormalities are profound enough to increase mortality substantially.

[Table 1](#TB02477-1){ref-type="table"} (based on Vincent et al [@JR02477-53] ) shows the potential values that contribute to the SOFA score.

###### Potential values that contribute to the SOFA score [a](#FN02477-2){ref-type="table-fn"}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SOFA score                               1                2                                                       3                                             4
  ---------------------------------------- ---------------- ------------------------------------------------------- --------------------------------------------- ------------------------------------------------
  *Respiration*\                           \<400            \<300                                                   \<200 (with respiratory support)              \<100 (with respiratory support)
  PaO ~2~ /FiO ~2~\                                                                                                                                               
  (mm Hg)                                                                                                                                                         

  *Coagulation*\                           \<150            \<100                                                   \<50                                          \<50
  10 ^−3^ /platelets/mm                                                                                                                                           

  *Liver*\                                 1.2--1.9\        2--5.9\                                                 6--11.9\                                      \>12\
  Bilirubin mg/dL\                         (20--32)         (33--101)                                               (102--204)                                    (\>204)
  (μM)                                                                                                                                                            

  *Cardiovascular*\                        MA *p*  \< 70\   Dopamine ≤ 5 [b](#FN02477-3){ref-type="table-fn"} or\   Dopamine \> 5\                                Dopamine \> 15\
  Hypotension                              mm Hg            dobutamine (any dose)                                   or epinephrine ≤0.1 or norepinephrine ≤ 0.1   or epinephrine \> 0.1 or norepinephrine \> 0.1

  *CNS*\                                   13--14           10--12                                                  6--9                                          \<6
  Glasgow Coma Score                                                                                                                                              

  *Renal*\                                 1.2--1.9\        2--3.4\                                                 3.5--4.9\                                     \>5\
  Creatinine, mg/dL (μM) or urine output   (110--170)       (171--299)                                              (300--440)\                                   (\>440)\
                                                                                                                    Or \<500 mL/d                                 or \<200 mL/d
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: CNS, central nervous system; SOFA, Sequential (Sepsis-Related) Organ Failure Assessment.

Based on Vincent et al [@JR02477-53] and shows the potential values that contribute to the SOFA score.

Catecholamine and adrenergic agents administered for at least 1 hour; doses in μg/kg/min.

Absent from [Fig. 1](#FI02477-1){ref-type="fig"} , and from the usual commentaries of this type, is any significant role of coagulopathies, although these too are a well-established accompaniment of SIRS/sepsis, [@JR02477-54] [@JR02477-55] [@JR02477-56] [@JR02477-57] [@JR02477-58] [@JR02477-59] [@JR02477-60] [@JR02477-61] [@JR02477-62] [@JR02477-63] [@JR02477-64] [@JR02477-65] [@JR02477-66] [@JR02477-67] [@JR02477-68] [@JR02477-69] and they will be our focus here. They form part of an emerging systems biology analysis, [@JR02477-16] [@JR02477-18] [@JR02477-70] [@JR02477-71] [@JR02477-72] [@JR02477-73] [@JR02477-74] [@JR02477-75] [@JR02477-76] [@JR02477-77] [@JR02477-78] [@JR02477-79] [@JR02477-80] in which iron dysregulation and an initially minor infection (e.g., in rheumatoid arthritis [@JR02477-81] [@BR02477-82] ) are seen to underpin the etiology of many chronic inflammatory diseases normally considered (as once were gastric ulcers [@JR02477-83] ) to lack a microbial component.

Here we develop these ideas for those conditions that are recognized as involving a genuine initial microbial invasion, together with sepsis and inflammation driven (in particular) by the cell wall components of bacteria (although we note that the same kinds of arguments apply to viruses [@JR02477-84] and to other infections).

Normal Blood Coagulation and Coagulopathies
===========================================

Historically, there are two main pathways of activation described that lead "normal" blood coagulation to form a clot, as occurs, for example, in response to vessel wall damage or exposure of blood to negatively charged surfaces. They have been expertly reviewed many times [@JR02477-85] [@JR02477-86] [@JR02477-87] [@JR02477-88] [@JR02477-89] [@JR02477-90] (e.g., are known in the older literature, respectively, as "extrinsic" and "intrinsic" pathways). [Fig. 2](#FI02477-2){ref-type="fig"} shows a basic model of coagulation (redrawn from Kell and Pretorius [@JR02477-74] under a CC-BY license); typically, assembly of fibrin fibers proceeds in a stepwise fashion. In short, after damage to a blood vessel, collagen is exposed and factor (F) VII interacts with tissue factor (TF), forming a complex called TF-FVIIa. FXa and its cofactor Va form the prothrombinase complex and activate thrombin through prothrombin. Finally, the terminal stages of the coagulation pathway happens, where a cross-linked fibrin polymer is formed as a result of fibrinogen (typically present in plasma at 2--4 g/L) conversion to fibrin and cross-linking due to the activation of FXIII, a transglutaminase. Thrombin activates FXIII into FXIIIa, which, in turn, acts on soluble and insoluble fibrin to polymerize it into insoluble cross-linked fibrin clot. This fibrin clot, when viewed under a scanning electron microscope, consists of individually visible fibrin fibers, discussed in the next paragraphs (see [Fig. 3A](#FI02477-3){ref-type="fig"} for a representative healthy clot structure created when thrombin is added to plasma. [@JR02477-74] [@JR02477-91] [@JR02477-92] [@JR02477-93]

![The classical coagulation pathways, where assembly of fibrin fibers proceeds in a stepwise fashion (redrawn from Kell and Pretorius [@JR02477-74] under an open access CC-BY license).](10-1055-s-0037-1604108-i02477-2){#FI02477-2}

![The results of thrombin-mediated blood clotting. **(A--C)** Micrographs taken with a Zeiss LSM 800 superresolution Airyscan confocal microscopy using the α Plan-Apochromat 63x/1.46 Oil DIC M27 Elyra objective. **(D)** Micrograph taken with a Zeiss LSM 510 META confocal microscope with a Plan-Apochromat 63x/1.4 Oil DIC objective. ( **A** ) Healthy platelet poor plasma (PPP) with added thioflavin T (ThT) (5-μM exposure concentration) and thrombin. ( **B** ) The same PPP, with added lipopolysaccharide (LPS) (0.2 ng/L exposure concentration), followed by addition ThT and thrombin. ( **C** ) The same PPP, with added LPS followed by LPS-binding protein (2 ng/L final exposure concentration) followed by addition ThT and thrombin. ( **D** ) PPP, with added LPS (0.2 ng/L exposure concentration), followed by addition ThT and thrombin.](10-1055-s-0037-1604108-i02477-3){#FI02477-3}

The normal picture of fibrinogen polymerization involves the removal of two fibrinopeptides (i.e., fibrinopeptides A and B) from fibrinogen, which is normally rich in α-helices, leading to its self-association through "knobs and holes," but with otherwise no major changes in secondary structure. [@JR02477-77] [@JR02477-80]

Coagulopathies occur when the rate of clot formation or dissolution is unusually fast or slow, and in the case of chronic inflammatory diseases, these seem largely to coexist as hypercoagulation and hypofibrinolysis, arguably implying a common cause. [@JR02477-74] In a series of papers, we have shown in several diseases, such as stroke, [@JR02477-94] [@JR02477-95] [@JR02477-96] type 2 diabetes, [@JR02477-93] [@JR02477-97] Alzheimer\'s disease, [@JR02477-79] [@JR02477-98] [@JR02477-99] and hereditary hemochromatosis, [@JR02477-92] that the fibrin clots induced by added thrombin adopted the form of "dense matted deposits" instead of their usual "spaghetti-like" appearance. The same kinds of effect could also be induced by unliganded (i.e., free) iron, [@JR02477-92] [@JR02477-100] [@JR02477-101] [@JR02477-102] although no molecular explanation was (or could be) given. We pick this up in the Amyloid-Like Conformational Transitions in Fibrin(ogen) section. First however, we need to deal with two other topics.

Endotoxin-Induced "Disseminated Intravascular Coagulation"
----------------------------------------------------------

Endotoxin (LPS) may also induce a runaway form of hypercoagulation [@JR02477-57] [@JR02477-103] [@JR02477-104] [@JR02477-105] [@JR02477-106] [@JR02477-107] [@JR02477-108] [@JR02477-109] [@JR02477-110] [@JR02477-111] [@JR02477-112] [@JR02477-113] [@JR02477-114] [@JR02477-115] [@JR02477-116] [@JR02477-117] known as disseminated intravascular coagulation (DIC). There is significant evidence now that DIC is reasonably well defined [@JR02477-46] [@JR02477-118] [@JR02477-119] [@JR02477-120] and that it can directly lead to MOF and death (Cunningham and Nelson, [@JR02477-121] and see the following). We hypothesize here that the form of clotting in DIC in fact involves autocatalytic fibrin(ogen) self-organization leading to amyloid formation, which is consistent with the faster clot formation in the presence of endotoxin [@JR02477-98] and which we have recently shown can occur in vitro with miniscule amounts of LPS. [@JR02477-80] In particular, this may be a major contributor to the various stages of sepsis, SIRS, MODS, and ultimately of organismal death.

Prions, Protein Free Energies, and Amyloid Proteins
---------------------------------------------------

Although it was originally shown that at least some proteins, when denatured and renatured, could revert to their original conformation, [@JR02477-122] [@JR02477-123] implying that this was (isoenergetic with) the one of lowest free energy, this is now known not to be universal. Leaving aside chaperones and the like, one field in which proteins of the same sequence are well known to adopt radically different conformations, with a much more extensive β-sheet component (that is indeed thermodynamically more stable), is that of prion biology. [@JR02477-124] [@JR02477-125] Thus, the prion protein is normally in an α-helix-rich conformation known as PrP ^c^ . However, it can also adopt a proteinase K-resistant form of the same sequence, known as PrP ^Sc^ . [@JR02477-126] [@JR02477-127] [@JR02477-128] [@JR02477-129] [@JR02477-130] [@JR02477-131] The PrP ^c^ and PrP ^sc^ conformations and the catalysis of the conversion to itself by the latter of the former are very well known. The key point for us here, however, is indeed that this definitely implies [@JR02477-77] [@JR02477-124] [@JR02477-125] [@JR02477-128] [@JR02477-132] [@JR02477-133] [@JR02477-134] [@JR02477-135] [@JR02477-136] that proteins that may initially fold into a certain, ostensibly "native," conformation can in fact adopt stable and more β-sheet-rich conformations of a lower free energy, separated from that of the original conformation by a potentially significant energy barrier.

Amyloid-Like Conformational Transitions in Fibrin(ogen)
-------------------------------------------------------

As mentioned earlier, the general view (also see the following) is that no major secondary structural changes occur during normal fibrin formation. [@JR02477-77] [@JR02477-85] [@JR02477-87] However, we know of at least three circumstances in which fibrin can (i.e., is known to) adopt a β-sheet-rich conformation: (1) in the case of specific mutant sequences of the fibrinogen a chain, [@JR02477-137] [@JR02477-138] [@JR02477-139] [@JR02477-140] [@JR02477-141] [@JR02477-142] [@JR02477-143] (2) when fibrin is stretched mechanically beyond a certain limit, [@JR02477-144] [@JR02477-145] [@JR02477-146] [@JR02477-147] [@JR02477-148] [@JR02477-149] [@JR02477-150] and (3) when formed in the presence of certain small molecules, including bacterial LPS. [@JR02477-76] [@JR02477-80] [@JR02477-151] Thus, it is well established that fibrin can form β-sheet-rich amyloids, although it is assumed that conventional blood clotting involves only a "knobs-and-holes" mechanism, without any major changes in secondary structure. [@JR02477-85] [@JR02477-86] [@JR02477-87] [@JR02477-88] [@JR02477-89] [@JR02477-90] [@JR02477-152] [@JR02477-153] We hypothesize here that the "dense matted deposits" seen earlier are in fact β-sheet-rich amyloids, and that it is this coagulopathy in particular that contributes significantly to the procession of sepsis along or through the cascade of toxicity outlined in [Fig. 1](#FI02477-1){ref-type="fig"} . To be specific, we consider that the binding of the LPS must be to fibrinogen itself since only this is preexisting and we have demonstrated it directly using isothermal calorimetry. [@JR02477-80] We note too that there is almost no "free" LPS except immediately after its addition/liberation from a bacterium, and that the kinetics of fibrinogen polymerization during thrombin-induced clotting are so fast that it is not necessary to invoke subsequent binding of LPS to protofibrils and so on as part of the mechanism of amyloidogenesis and toxicity.

In particular, thioflavin T (ThT) is a stain whose fluorescence (when excited at 440--450 nm or so) is massively enhanced upon binding to β-sheet-rich amyloids [@JR02477-154] [@JR02477-155] [@JR02477-156] [@JR02477-157] [@JR02477-158] [@JR02477-159] [@JR02477-160] [@JR02477-161] [@JR02477-162] [@JR02477-163] (whose conformation differs markedly from that of "normal" β-sheets in proteins, else it would stain most such proteins). [Fig. 3A](#FI02477-3){ref-type="fig"} to [C](#FI02477-3){ref-type="fig"} show micrographs taken of clots with a Zeiss superresolution microscope using Airyscan technology (Carl Zeiss), and [Fig. 3D](#FI02477-3){ref-type="fig"} shows a micrograph taken using a Zeiss confocal microscope (see legend for specific detail). [Fig. 3A](#FI02477-3){ref-type="fig"} is a micrograph of healthy platelet poor plasma (PPP) with added ThT and thrombin. This is a representative micrograph to show "normal" clot structure, whereas [Fig. 3B](#FI02477-3){ref-type="fig"} and [D](#FI02477-3){ref-type="fig"} shows healthy PPP with added LPS and ThT. High-resolution Airyscan technology ( [Fig. 3B](#FI02477-3){ref-type="fig"} ) shows ThT binding to areas where β-sheet-rich amyloids were induced by LPS. [Fig. 3C](#FI02477-3){ref-type="fig"} shows PPP preexposed to LPS, followed by exposure to LPS-binding protein, ThT, and thrombin. LPS-binding protein was able to reverse the formation of the β-sheet-rich amyloids areas created by preexposure to LPS. Confocal microscopy ( [Fig. 3D](#FI02477-3){ref-type="fig"} ) also shows this ThT binding to β-sheet-rich amyloid areas. However, individual binding areas are not as clearly visible as with the Airyscan technology. Nonetheless, the extent of β-amyloid formation in the LPS-treated over the two controls is very striking.

We also note the important analyses of Strickland et al to the effect that β-amyloid can interact with fibrin(ogen) [@JR02477-164] [@JR02477-165] [@JR02477-166] [@JR02477-167] [@JR02477-168] [@JR02477-169] [@JR02477-170] and cause it to become refractory to fibrinolysis. [@JR02477-170] [@JR02477-171] [@JR02477-172] [@JR02477-173]

Inflammatory Nature of Fibrin
=============================

The fact that fibrin itself is, or can be, inflammatory is well established [@JR02477-108] [@JR02477-174] [@JR02477-175] [@JR02477-176] [@JR02477-177] [@JR02477-178] [@JR02477-179] and does not need further elaboration. Our main point here is that in none of these studies has it been established whether (or to what extent) the fibrin is in an amyloid form or not so far. Certainly, it is very well established that amyloids can be inflammatory. [@JR02477-180] [@JR02477-181] [@JR02477-182] [@JR02477-183]

Further Evidence for the "Trigger" Role of LPS in Large-Scale Amyloid Formation
===============================================================================

In our previous studies, [@JR02477-80] we found that LPS (endotoxin) at a concentration of just 0.2 ng/L could trigger the conversion of some 10 ^8^ times more fibrinogen molecules, [@JR02477-80] and that the fibrin fibers so formed were amyloid in nature. (A very large amplification of structural molecular transitions could also be induced by LPS in a nematic liquid crystal. [@JR02477-184] [@JR02477-185] [@JR02477-186] ) Only some kind of autocatalytic processes can easily explain this kind of polymerization, just as occurs in prions, [@JR02477-77] [@JR02477-129] [@JR02477-131] where iron may also be involved. [@JR02477-70] [@JR02477-71] [@JR02477-187] [@JR02477-188] [@JR02477-189] To be explicit, the only feasible explanation is one in which an initial fibrinogen molecule with bound LPS adopts, at least on the loss of its fibrinopeptides, conformations in which the subsequent fibrinopeptide-less fibrinogens must also change their conformations to bind to it and so on as fibrinogens become protofibrils, protofibrils become fibrils, and so on. Put another way, if LPS is the only (and highly substoichiometric) addition to thrombin-induced fibrin formation, there must be an "autocatalytic process," somewhat analogous to a prion, that must be taking place since rather than having conventional strands of fibrin, we have amorphous, denatured β sheets.

Cytotoxicity of Amyloids
========================

Cytotoxicity of amyloids is so well known [@JR02477-98] [@JR02477-182] [@JR02477-190] [@JR02477-191] [@JR02477-192] [@JR02477-193] [@JR02477-194] [@JR02477-195] [@JR02477-196] [@JR02477-197] that it barely needs rehearsing. However, the relative toxicities of soluble material, protofibrils, fibrils, and so on are less well understood, [@JR02477-198] in part because they can equilibrate with each other even if added as a "pure" component (of a given narrow NB equilibrate range). Although the larger fibrils are much more easily observable microscopically, there is a great deal of evidence that it is the smaller ones that are the more cytotoxic. [@JR02477-199] [@JR02477-200] [@JR02477-201] [@JR02477-202] [@JR02477-203] [@JR02477-204] [@JR02477-205] [@JR02477-206] [@JR02477-207] [@JR02477-208] [@JR02477-209] [@JR02477-210] [@JR02477-211] [@JR02477-212] [@BR02477-213] [@JR02477-214] [@JR02477-215] [@JR02477-216] So far as is known, almost all (cf. Holm et al [@JR02477-217] ) the established forms of amyloid are cytotoxic. However, the tests have not yet been performed for the fibrin version since it has only very recently been discovered. [@JR02477-77] [@JR02477-80] This is an urgent task for the future.

Sequelae Consistent with the Role of Amyloids in the "Sepsis Cascade" to Organ Failure and Death
================================================================================================

If vascular or systemic amyloidogenesis really is a significant contributor to the worsening patient conditions as septic shock moves toward MOF/MODS and death, with the cytotoxic amyloids (whether from fibrin and/or otherwise) in effect being largely responsible for the MOF, then one might expect it to be visible as amyloid deposits in organs such as the kidney (whether as biopsies or postmortem). It is certainly possible to find evidence for this, [@JR02477-218] [@JR02477-219] [@JR02477-220] [@JR02477-221] [@BR02477-222] [@JR02477-223] and our proposal is that such amyloid should be sought using ThT or other suitable staining in autopsy tissue.

Hypo- or Hypertensive States
============================

A hallmark of most of the chronic, inflammatory diseases that we have considered here and elsewhere (as cited) is that they are either normotensive or (to varying degrees) hypertensive. By contrast, sepsis and septic shock are strongly hypotensive (accompanied by hypoperfusion), [@JR02477-224] [@JR02477-225] [@JR02477-226] [@JR02477-227] [@JR02477-228] and their normalization is considered a crucial factor for lowering mortality. Consequently, this bears a brief discussion. Of course, at one level, it is common in biology that something can be a stimulus (e.g., of blood pressure) at a low concentration and can be an inhibitor at a high concentration (this is known as "hormesis" [@JR02477-229] [@JR02477-230] [@JR02477-231] ). At a descriptive level, this is clearly happening here. As it stands, however, we can find no literature that has compared changes in tension as the dose of endotoxin is varied, with the doses given in such studies of endotoxin-induced shock normally being sufficient to induce significant hypotension. [@JR02477-232] [@JR02477-233] [@JR02477-234] It is, however, of considerable interest that this endotoxin-induced hypotension (and other sequelae) could be relieved by antithrombin (e.g., [@JR02477-233] [@JR02477-235] [@JR02477-236] [@JR02477-237] [@JR02477-238] [@JR02477-239] [@JR02477-240] [@JR02477-241] [@JR02477-242] [@JR02477-243] [@JR02477-244] [@JR02477-245] [@JR02477-246] [@JR02477-247] ), implying a contributing role for coagulopathies in the hypotension otherwise observed, albeit other mechanisms are possible. [@JR02477-238]

How Might This Understanding Lead to Improved Treatment Options?
================================================================

Over the years, there have been many high-profile failures of therapies for various aspects of severe inflammation, sepsis, septic shock, and SIRS. These include therapies aimed at endotoxin itself (Centoxin), [@JR02477-248] [@JR02477-249] [@JR02477-250] and the use of recombinant activated protein C [@JR02477-251] or Drotrecogin alfa. [@JR02477-2] [@JR02477-250] [@JR02477-252] [@JR02477-253] Anticytokine and anti-inflammatory treatments have also had, at best, mixed results. [@JR02477-254] [@JR02477-255]

However, the overall picture that we have come to is given in [Fig. 4](#FI02477-4){ref-type="fig"} . This implies that we might hope to stop the progress of the sepsis/SIRS/MODS cascade at any (preferably several [@JR02477-256] ) of several other places, including through iron chelation, [@JR02477-70] [@JR02477-71] [@JR02477-257] [@JR02477-258] the use of anti-inflammatory agents, the use of anticoagulants such as heparin [@JR02477-178] or antithrombin, [@JR02477-233] [@JR02477-238] [@JR02477-243] and the use of stimulants of fibrinolysis. [@JR02477-259] The success of heparin [@JR02477-260] [@JR02477-261] (see also Zarychanski et al, van Roessel et al, and Okamoto et al [@JR02477-262] [@JR02477-263] [@JR02477-264] ) is especially noteworthy in the context of the present hypothesis, though it may have multiple (not simply directly anticoagulant) actions. [@JR02477-265] [@JR02477-266] The same is true of antithrombin. [@JR02477-233] [@JR02477-235] [@JR02477-236] [@JR02477-237] [@JR02477-238] [@JR02477-239] [@JR02477-240] [@JR02477-241] [@JR02477-242] [@JR02477-243] [@JR02477-244] [@JR02477-245] [@JR02477-246] [@JR02477-247] [@JR02477-267] [@JR02477-268] However, antithrombin has also not been efficacious, especially in combination with heparin [@JR02477-269] and is globally not recommended in sepsis therapy guidelines. [@JR02477-4] [@JR02477-270] Indeed, suppressing coagulation in sepsis globally may be inimical, as it is thought to serve a protective role in the initial stages of the disease. [@JR02477-271] It is also noteworthy that high-density lipoprotein (HDL) cholesterol is a protective against sepsis [@JR02477-18] [@JR02477-272] [@JR02477-273] [@JR02477-274] (HDL are antioxidant [@JR02477-275] and anti-inflammatory [@JR02477-276] and can also bind and neutralize endotoxin [@JR02477-277] [@JR02477-278] [@JR02477-279] ). Therefore, the beneficial role of certain statins in sepsis [@JR02477-280] [@JR02477-281] should be seen in the context of their much more potent anti-inflammatory role [@JR02477-70] rather than in any (modest) role involved in lowering overall serum cholesterol. Phospholipid emulsions may also serve. [@JR02477-282]

![A systems biology model of the development of coagulopathies during sepsis, systemic inflammatory response syndrome, and multiple organ dysfunction syndrome. An elementary systems biology model of how iron dysregulation can stimulate dormant bacterial growth that can, in turn, lead to antigen production (e.g., of lipopolysaccharide \[LPS\]) that can then trigger inflammation leading to cell death [@JR02477-70] [@JR02477-71] and a variety of diseases. While it is recognized that this simple diagram is very far from capturing the richness of these phenomena, there is abundant evidence for each of these steps, starting with ( **0** ) an infection/gut dysbiosis and the creation of a (dormant) blood and tissue microbiome. This is typically accompanied by ( **1** ) iron dysregulation, which is known to be present in many diseases, as both cause and result ( **5** ) and as an important cause of inflammation ( **6** ) and even organism death ( **10** ). Iron, in turn, feeds bacterial growth ( **2** ), leading to production of, for example, LPS with an accompanying upregulated inflammatory cytokine profile ( **3** ), leading to disease ( **4** ). In inflammation both apoptotic death ( **8** ) and coagulopathies ( **7** ) are well-known phenomena. In turn, apoptotic death can lead to organism death ( **9** ).](10-1055-s-0037-1604108-i02477-4){#FI02477-4}

We have noted previously (reviewed in Kell and Pretorius [@JR02477-74] ) that such "dense matter deposits" (now recognized as amyloid forms) are much more resistant to fibrinolysis than is "normal" fibrinogen. The working hypothesis here is that the β-sheet-rich forms are more resistant to proteolysis because (as in prions, where the structures are known) the residues normally targeted by the relevant proteases are no longer exposed. Clearly, the removal of such structures would benefit from the development of novel proteases to which they are susceptible.

Recombinant soluble human thrombomodulin (TM-α) is a novel anticoagulant drug and has been found to have significant efficacy in the treatment of sepsis-based DIC, [@JR02477-247] [@JR02477-283] [@JR02477-284] [@JR02477-285] [@JR02477-286] [@JR02477-287] [@JR02477-288] [@JR02477-289] [@JR02477-290] [@JR02477-291] [@JR02477-292] [@JR02477-293] albeit fully powered randomized trials are awaited, [@JR02477-294] [@JR02477-295] again adding further weight to our hypothesis. As Okamoto et al [@JR02477-264] point out, "In the European Union and the USA, the 2012 guidelines of the Surviving Sepsis Campaign do not recommend treatment for septic DIC. [@JR02477-4] [@JR02477-296] In contrast, in Japan, aggressive treatment of septic DIC is encouraged," [@JR02477-297] [@JR02477-298] [@JR02477-299] [@JR02477-300] and that "that Japan is one of the countries that most effectively treats patients with septic DIC." [@JR02477-264] A recent meta-analysis of randomized controlled trials for the efficacy and safety of anticoagulant therapy demonstrated that such therapy has a survival benefit in those with sepsis-induced DIC, but not in the overall population with sepsis or even in populations with sepsis-induced coagulopathy. [@JR02477-271] We note that the influence of soluble TM may be mediated by its indirect thrombin inhibition by binding and not localizing it to a site where protein C is activated.

Thus, if it is accepted that the type of fibrin that is formed is substantially of the amyloid variety, then anticoagulant and other drugs that inhibit or reverse such amyloid processes should also be of value, [@JR02477-301] as they seem to be in Alzheimer-type dementia. [@JR02477-165] [@JR02477-302] [@JR02477-303]

Concluding Remarks
==================

We conclude by showing our line of thought in [Fig. 5](#FI02477-5){ref-type="fig"} . There is by now abundant evidence that coagulopathies involving fibrin clots are a major part of sepsis, SIRS, septic shock, MODS, DIC, and organismal death. We have invoked further evidence that the type of fibrin involved is an amyloid form and have suggested that it is this that is especially damaging. This definitely needs to be tested further, for instance, using appropriate stains [@JR02477-155] [@JR02477-304] and/or X-ray measurements [@JR02477-305] [@JR02477-306] [@JR02477-307] in concert with cellular toxicity assays. The former could easily be performed in or near the intensive therapy unit. LPS and other substances have now been shown to cause anomalous forms of fibrin, which opens up many novels lines of work, such that reducing or eliminating them might be worthwhile, for example, with LPS-binding protein. Finally, as a corollary of the above, we suggest that anticoagulant therapies that inhibit or reverse those β-amyloid forms of fibrin production will be especially valuable. To this end, lowering the levels of fibrinogen itself would seem to be a desirable aim. [@JR02477-308]

![A schematic representation outlining our hypothesis based on current knowledge **(A)** , experimental evidence for our hypothesis **(B)** , hypothetical evidence ( **C** ), and finally our thoughts on (new) treatment regime approaches and early disease diagnosis ( **D** ).](10-1055-s-0037-1604108-i02477-5){#FI02477-5}
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